Active acromegaly is almost always the result of a benign growth hormone (GH)-secreting adenoma of the pituitary gland. Because the same pituitary stem cell can produce both GH and prolactin (PRL), many acromegalic patients also have hyperprolactinemia. The advantages of surgical excision of pituitary adenomas associated with acromegaly include: (1) prompt decrease in GH; (2) reliable and immediate relief of the mass effect from the tumor (decompression of the optic nerves and chiasm), and (3) the opportunity to obtain tumor tissue for characterization and investigative study. Currently, more than 97% of operations for removal of pituitary tumors associated with acromegaly are done using the transsphenoidal approach rather than craniotomy. Technical advances to make the surgery safer continue to evolve, and include endoscopic approaches, computer-guided image-based intraoperative visualization, and intraoperative magnetic resonance imaging. Criteria for satisfactory remission of acromegaly after surgery are the same as those used for medical management. They include normal insulin-like growth factor (IGF)-I and suppression of GH to undetectable levels (<1.0 ng/ml) during an oral glucose tolerance test (OGTT). Data from a recent series of 86 patients operated upon for acromegaly at the University of Virginia and followed for more than 1 year have been reviewed. In patients receiving surgery as the initial procedure, 67% had a normal IGF-I, and 52% suppressed to <1.0 ng/ml in an OGTT. There was one true recurrence of disease diagnosed 81 months after surgery. Results are best in patients with noninvasive microadenomas. Gamma knife radiosurgery has been a valuable adjunct in those patients who fail to achieve postoperative remission. Pathological evaluation of the tumors revealed that 16% expressed GH only, 25% stained for GH and glycoprotein hormones (follicle stimulating hormone, thyroid hormone, thyroid stimulating hormone, α-subunit), 21% for GH and PRL, and 33% for GH, PRL and glycoprotein hormones. There was one acidophil stem cell tumor and 10% had the mammosomatotroph subtype. This contemporary series was free of mortality or serious complications. One patient had a transient cerebrospinal fluid leak and 3 developed transient SIADH with hyponatremia. Surgical treatment remains an important aspect of the combined management of patients with acromegaly.

Keywords:
Acromegaly, Pituitary adenoma, Transsphenoidal surgery, Growth hormone
1.
Laws ER Jr, Piepgras DG, Randall RV, Abboud CF: Neurosurgical management of acromegaly – Results in 82 patients treated between 1972 and 1977. J Neurosurg 1979;50:454–461.
2.
Cushing H: Partial hypophysectomy for acromegaly: With remarks on the function of the hypophysis. Ann Surg 1909;50:1002–1017.
3.
Ciric I, Ragin A, Baumgartner C, Pierce D: Complications of transsphenoidal surgery: Results of a national survey, review of the literature, and personal experience. Neurosurgery 1997;40:225–237.
4.
Giustina A, Barkan A, Casanueva FF, Cavagnini F, Lawrence F, Ken H, Johannes V, Wass J, von Werde K, Melmed S: Criteria for cure of acromegaly: A consensus statement. J Clin Endocrinol Metab 2000;85:526–529.
5.
Melmed S: Acromegaly. N Engl J Med 1990;322:966–977.
6.
Lissett CA, Peacey SR, Laing I, Tetlow L, Davis JRE, Shalet SM: The outcome of surgery for acromegaly: The need for a specialist pituitary surgeon for all types of growth hormone (GH) secreting adenoma. Clin Endocrinol 1998;49:653–657.
7.
Roelfsema F, van Dulken H, Frölich M: Long-term results of transsphenoidal pituitary microsurgery in 60 acromegalic patients. Clin Endocrinol 1985;23:555–565.
8.
van’t Verlaat J, Nortier J, Hendriks M, Bosma N, Graamans K, Lubsen H, Vasen H, Thijssen J, Croughs R: Transsphenoidal microsurgery as primary treatment in 25 acromegalic patients: Results and follow-up. Acta Endocrinol (Copenh) 1988;117:154–158.
9.
Losa M, Oeckler R, Schopohl J, Muller O, Alba-Lopez J, von Werder K: Evaluation of selective transsphenoidal adenomectomy by endocrinological testing and somatostatin-C measurement in acromegaly. J Neurosurg 1989;70:561–567.
10.
Fahlbusch R, Honegger J, Buchfelder M: Surgical management of acromegaly. Endocrinol Metab Clin North Am 1992;21:669–692.
11.
Tindall GT, Oyesiku NM, Watts NB, Clark RV, Christy JH, Adams DA: Transsphenoidal microneurosurgical removal of 250 pituitary adenomas. J Neurosurg 1993;48:13–22.
12.
Davis D, Laws ER Jr, Ilstrup D, Speed J, Caruso M, Shaw E, Abboud C, Scheithauer B, Root L, Schleck C: Results of surgical treatment of growth hormone-secreting pituitary adenomas. J Neurosurg 1993;79:70–75.
13.
Sheaves R, Jenkins P, Blackburn P, Huneidi AH, Afshar F, Medbak S, Grossman AB, Besser GM, Wass JAH: Outcome of transsphenoidal surgery for acromegaly using strict criteria for surgical cure. Clin Endocrinol 1996;45:407–413.
14.
Abosch A, Tyrell JB, Lamborn KR, Hannegan LT, Applebury CB, Wilson CB: Transsphenoidal microsurgery for growth hormone-secreting pituitary adenomas: Initial outcome and long-term results. J Clin Endocrinol Metab 1998;83:3411–3418.
15.
Swearingen B, Barber FG 2nd, Katznelson L, Biller BM, Grinspoon S, Klibanski A, Moayeri N, Black PM, Zervas N: Long-term mortality after transsphenoidal surgery and adjunctive therapy for acromegaly. J Clin Endocrinol Metab 1998;83:3419–3426.
16.
Freda PU, Wardlaw SL, Post KD: Long-term endocrinological follow-up evaluation in 115 patients who underwent transsphenoidal surgery for acromegaly. J Neurosurg 1998;89:353–361.
17.
Scheithauer BW, Kovacs K, Randall RV, Horvath E, Laws ER Jr: Pathology of excessive production of growth hormone. Clin Endocrinol 1986;15:665–681.
18.
Laws ER Jr, Scheithauer BW, Carpenter SM, Randall RV, Abboud CF: The pathogenesis of acromegaly: Clinical and immunocytochemical analysis in 75 patients. J Neurosurg 1985;63:35–38.
© 2000 S. Karger AG, Basel
2000
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.